You are here

EpiPen fallout builds as adviser backs dumping Mylan board

BT_20170614_EPI_2933923.jpg
Since acquiring the drug in 2007, Mylan has raised the price several times, to more than US$600 for a two-pack from about US$57 a shot.

Washington

MYLAN faces an increasing backlash over its handling of the EpiPen pricing controversy, as a top proxy adviser urged shareholders to oust the drugmaker's board.

Institutional Shareholder Services (ISS) said that the company's directors had failed to stop "significant

sentifi.com

Market voices on:

Powered by GET.comGetCom